Pharmacologic Treatment of Wet Type Age-related Macular Degeneration; Current and Evolving Therapies.

Hoda Shams Najafabadi,N. Daftarian,H. Ahmadieh,Z. Soheili

Published 2017 in Archives of Iranian medicine

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2017
Venue
Archives of Iranian medicine
Publication date
2017-08-01
Fields of study
Medicine
Identifiers
PMID 28846017
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar, PubMed

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

What Is Age-Related Macular Degeneration?
2024cited by this paper
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)
2018cited by this paper
Blockade of Tumor Necrosis Factor-Alpha: A Role for Adalimumab in Neovascular Age-Related Macular Degeneration Refractory to Anti-Angiogenesis Therapy?
2016cited by this paper
Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial
2015cited by this paper
Drugs in Phase II clinical trials for the treatment of age-related macular degeneration
2015cited by this paper
Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
2015cited by this paper
Current phase 1/2 research for neovascular age-related macular degeneration
2015cited by this paper
Future Therapies of Wet Age-Related Macular Degeneration
2015cited by this paper
TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY
2015cited by this paper
Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: A pilot study
2014cited by this paper
Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.
2014cited by this paper
Vision Related Quality of Life in Patients with Keratoconus
2014cited by this paper
Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
2014cited by this paper
CLINICAL EVALUATION OF PAZOPANIB EYE DROPS IN HEALTHY SUBJECTS AND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
2014cited by this paper
Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study.
2014cited by this paper
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
2014cited by this paper
Intravitreal Tumor Necrosis Factor-Alpha Inhibitors for Neovascular Age-Related Macular Degeneration Suboptimally Responsive to Antivascular Endothelial Growth Factor Agents: A Pilot Study from the Pan American Collaborative Retina Study Group
2013cited by this paper
Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.
2013cited by this paper
Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome.
2013cited by this paper
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
2013cited by this paper
Emergence of dual VEGF and PDGF antagonists in the treatment of exudative age-related macular degeneration
2013cited by this paper
Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration
2013cited by this paper
A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration
2013cited by this paper
Risk factors of age-related macular degeneration in Argentina.
2013cited by this paper
Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration
2013cited by this paper
KH902 suppresses high glucose‐induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF
2013cited by this paper
Bevacizumab vs ranibizumab—an appraisal of the evidence from CATT and IVAN
2013cited by this paper
LUCEDEX: A Prospective Study Comparing Ranibizumab plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Neovascular Age-Related Macular Degeneration
2013cited by this paper
Therapeutic targeting of the complement system in age‐related macular degeneration: a review
2012cited by this paper
Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
2012cited by this paper
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
2012cited by this paper
TOPICAL BROMFENAC AS AN ADJUNCTIVE TREATMENT WITH INTRAVITREAL RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
2012cited by this paper
Current trends in the pharmacotherapy of diabetic retinopathy.
2012cited by this paper
Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
2012cited by this paper
Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications
2012cited by this paper
Today and Future of Age-Related Macular Degeneration
2012cited by this paper
Influence of Ranibizumab on Vascular Endothelial Growth Factor Plasma Level and Endothelial Progenitor Cell Mobilization in Age-Related Macular Degeneration Patients: Safety of Intravitreal Treatment for Vascular Homeostasis
2011cited by this paper
Lasting Controversy on Ranibizumab and Bevacizumab
2011cited by this paper
Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials
2011cited by this paper
INTRAVITREAL BEVACIZUMAB VERSUS COMBINED INTRAVITREAL BEVACIZUMAB AND TRIAMCINOLONE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Six-Month Results of a Randomized Clinical Trial
2011cited by this paper
A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration.
2011cited by this paper
PlGF gene knockdown in human retinal pigment epithelial cells
2011cited by this paper
Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
2011cited by this paper
The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment
2011cited by this paper
Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration
2011cited by this paper
Regulation of angiogenesis by macrophages.
2010cited by this paper
Therapeutic antibodies in ophthalmology
2010cited by this paper
Age-related macular degeneration and antioxidant vitamins: recent findings
2010cited by this paper
A RANDOMIZED PILOT STUDY OF SYSTEMIC IMMUNOSUPPRESSION IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH CHOROIDAL NEOVASCULARIZATION
2010cited by this paper
Nonsteroidal anti-inflammatory drugs in ophthalmology.
2010cited by this paper
RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027.
2010cited by this paper
Immune activation in retinal aging: a gene expression study.
2010cited by this paper
Complement, age-related macular degeneration and a vision of the future.
2010cited by this paper
Residue-resolved stability of full-consensus ankyrin repeat proteins probed by NMR.
2010cited by this paper
Topical nepafenac for treatment of exudative age‐related macular degeneration
2010cited by this paper
Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
2010cited by this paper
Symmetrical central choroido-retinal disease occurring in senile persons
2009cited by this paper
Dendritic cells in chronic obstructive pulmonary disease
2009cited by this paper
Emerging Pharmacologic Therapies for Wet Age-Related Macular Degeneration
2009cited by this paper
SHORT-TERM EFFECTIVENESS OF INTRAVITREAL BEVACIZUMAB VERSUS RANIBIZUMAB INJECTIONS FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
2009cited by this paper
Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells
2009cited by this paper
Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration.
2009cited by this paper
RNAI Therapeutics: A Two-Year Update
2009cited by this paper
Associations between Lutein, Zeaxanthin, and Age-Related Macular Degeneration: An Overview
2009cited by this paper
Immunoregulatory functions of mTOR inhibition
2009cited by this paper
Topical administration of a multi‐targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema
2008cited by this paper
Alternate serotype adenovector provides long-term therapeutic gene expression in the eye
2008cited by this paper
Dendritic cells in chronic obstructive pulmonary disease: new players in an old game.
2008cited by this paper
Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project.
2008cited by this paper
Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
2008cited by this paper
Pegaptanib sodium for ocular vascular disease
2007cited by this paper
Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration
2007cited by this paper
Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.
2007cited by this paper
Ranibizumab for neovascular age-related macular degeneration.
2007cited by this paper
The role of complement system in ocular diseases including uveitis and macular degeneration.
2007cited by this paper
Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions.
2007cited by this paper
A Dual VEGFR/JAK2 Kinase Inhibitor Suitable for Topical Delivery Inhibits Choroid Neovascularization in Mice
2007cited by this paper
EFFECT OF ADJUNCTIVE DICLOFENAC WITH VERTEPORFIN THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION: Phase II Study
2007cited by this paper
Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients
2006cited by this paper
Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
2006cited by this paper
Ranibizumab for neovascular age-related macular degeneration.
2006cited by this paper
Development of atrophy of the retinal pigment epithelium around disciform scars
2006cited by this paper
Anecortave acetate in the treatment of age-related macular degeneration
2006cited by this paper
DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
2006cited by this paper
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.
2006cited by this paper
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.
2006cited by this paper
Age-related macular degeneration.
2006cited by this paper
Diet and age-related macular degeneration: expanding our view.
2006cited by this paper
Squalamine lactate for exudative age-related macular degeneration.
2006cited by this paper
Anecortave acetate in the treatment of age-related macular degeneration
2006cited by this paper
Ocular Pharmacokinetics of Pigment Epithelium–Derived Factor (PEDF) Following Adenovector–Based Gene Delivery Indicate That Low Doses of PEDF Are Therapeutic
2005cited by this paper
Angiogenesis inhibitors: an upcoming therapy for cancer and wet age-related macular degeneration.
2005cited by this paper
ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow.
2005cited by this paper
AL–39324: A Potential 2nd Generation Agent for the Treatment of Pathologic Choroidal Neovascularization (CNV)
2005cited by this paper
Intravitreal Methotrexate Injections in the Treatment of Choroidal Neovascularization in Age–Related Macular Degeneration
2005cited by this paper
AG–013958 (VEGFR Inhibitor) Achieves Effective Choroidal Concentrations With Minimal Systemic Effects in Cynomolgus Monkeys and Humans With Age–Related Macular Disease
2005cited by this paper
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2004cited by this paper
Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization.
2004cited by this paper
INTRAVITREAL INJECTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR SMALL INTERFERING RNA INHIBITS GROWTH AND LEAKAGE IN A NONHUMAN PRIMATE, LASER-INDUCED MODEL OF CHOROIDAL NEOVASCULARIZATION
2004cited by this paper
Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins.
2003cited by this paper

CITED BY

From optogenetic to thermogenetic gene therapy for vision restoration, perspectives article
2026cites this paper
Hybrid Integent Staging of Age-Related Macular Degeneration for Decision-Making on Patient Management Tactics
2025cites this paper
MiRGD peptideticle targeted delivery of hinge-truncated soluble VEGF receptor 1 fusion protein to the retinal pigment epithelium cell line and newborn mice retina.
2025cites this paper
Engineered red Opto-mGluR6 Opsins, a red-shifted optogenetic excitation tool, an in vitro study
2024cites this paper
Retinal and Choroidal Neovascularization Antivascular Endothelial Growth Factor Treatments: The Role of Gene Therapy
2022cites this paper
Pharmacological advances in the treatment of age-related macular degeneration.
2020cites this paper
Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration.
2020cites this paper